Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for rare endocrine diseases and endocrine-related tumors. They are driven by a mission to provide effective and convenient treatment options for patients who currently face significant challenges in managing their conditions. Their focus on oral, small molecule drug candidates represents a significant advancement in the field, offering potential for improved patient outcomes and quality of life.

Crinetics has a robust pipeline of internally discovered drug candidates, including paltusotine, a first-in-class oral somatostatin receptor type 2 (SST2) agonist, currently in Phase 3 clinical development for acromegaly. They are also developing CRN04894, an investigational oral ACTH antagonist, for the treatment of Cushing’s disease and congenital adrenal hyperplasia. Their commitment to research and development is evident in their ongoing clinical studies and preclinical efforts aimed at addressing a variety of endocrine conditions, including hyperparathyroidism, polycystic kidney disease, Graves’ disease, hyperinsulinism, diabetes, and obesity.

Crinetics Pharmaceuticals offers comprehensive employee benefits including health, dental, and vision insurance, an employee stock purchase plan (ESPP) at a discount, stock options, restricted stock units (RSUs), and a 401k with a company match. They also offer supplemental benefits that focus on physical, emotional, career, and financial well-being.

Crinetics Pharmaceuticals is a clinical-stage company focused on discovering, developing, and commercializing novel oral therapeutics for patients with rare endocrine diseases and endocrine-related tumors. The company is dedicated to building a leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. Crinetics has built a strong pipeline of drug candidates that are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

Crinetics promotes a culture of focused intensity where employees are passionate about their work and dedicated to improving the lives of patients with endocrine diseases. The company values a collaborative environment where individuals can contribute their creativity and intellect to tackle big challenges, ensuring their contributions are recognized and appreciated. Crinetics fosters a workplace where employees are encouraged to work hard, play nice, and smile lots, reflecting a positive and supportive atmosphere.

Crinetics Pharmaceuticals is committed to fostering a diverse, equitable, and inclusive workplace. The company recognizes that embracing diversity in thought, background, and experience is essential to achieving its mission of developing innovative therapies for people with endocrine diseases. This commitment is reflected in its values, which prioritize the wellbeing and perspectives of its employees, partners, and the patients they serve. Crinetics actively seeks to build a workforce that is representative of the diverse communities it serves, providing equal opportunities for all individuals to thrive and contribute their unique skills and perspectives.